BRAF and melanoma: To further support the link between the reduction of TPC2 expression and YAP/TAZ target gene activation, we also analysed a dataset from another study [37] that investigated the effect of the BRAF inhibitor Vemurafenib on the BRAFV600E A375 melanoma cell line, the mutant form of BRAF in this cell line being differentially sensitive to inhibition by Vemurafenib (Figure 6).